

Supplementary material

Predicting antibody neutralization efficacy in hypermutated epitopes using Monte Carlo simulations

Pep Amengual-Rigo ¹, Jorge Carrillo ², Julià Blanco ^{2,3,4} and Victor Guallar ^{1,5,*}

¹ Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain; jose.amengual@bsc.es

² IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; jcarrillo@irsicaixa.es (J.C.); jblanco@irsicaixa.es (J.B.)

³ Institut Germans Trias i Pujol, 08916 Badalona, Spain

⁴ School of Medicine, University of Vic–Central University of Catalonia, 08500 Vic, Spain

⁵ Catalan Institution for Research and Advanced Studies, 08010 Barcelona, Spain

* Correspondence: victor.guallar@bsc.es; Tel.: +34-934137727

Strain name	Clade	IC50 (VRC01)	Loop D	CD4 loop	β20-β21	V5-β24-a5
3365.v2.c20	A	0.025	ENITNNAKN	FNGS-SGGDLEITTHSF	KQIINMWQRAGQAIYA	GLILTRDGGNNNN---SSNETFRPGGGMDRDNW
BI369.9A	A	0.08	ENITNNVKT	FTNS-SGGDLEVTTHSF	RQIINMWQRTGQAMYA	GLLLTRDGGGN--N--NTNETFRPGGGMDRDNW
BS208.B1	A	0.005	ENITNNAKN	FANP-LGGDLEITTHSF	KQIINMWQRVGQAMYA	GILTRDGGY---N--NTNETFRPGGGMDRDNW
Q23.17	A	0.084	ENITNNAKI	FANS-SGGDLEITTHSF	KQIINMWQRAGQAIYA	GLLLTRDGGKD--N--NVNETFRPGGGMDRDNW
Q769.d22	A	0.012	ENITNNAKN	FNNS-LGGDLEITTHSF	KQIINMWQRVGQAIYA	GLILTRDGGIIN---STEETFRPGGGMDRDNW
Q769.h5	A	0.026	ENITNNAKN	FNNS-LGGDLEITTHSF	KQIINMWQRVGQAIYA	GLILTRDGGIINST--DTDEIFRPGGGMDRDNW
Q842.d12	A	0.013	ENITNNAKT	FANS-TGGDLEITTHSF	KQIINMWQRVGQAIYA	GLILTRDGGNT-N---STRETFRPGGGMDRDNW
QH209.14M.A2	A	0.008	ENFTNNAKN	FTNS-SGGDLEITTHSF	KQIINMWQRVGQAIYA	GLILTRDGGDDE---NNTETFRPGGGMDRDNW
3301.V1.C24	AC	0.155	ENLTDNVKT	FKPS-SGGDPEITTHSF	RQIINMWQGVGQAIYA	GLLLTRDGGSDG-N--STKETFRPGGGMDRDNW
3589.V1.C4	AC	0.132	KNLTDNAKT	FAKH-SGGDLEITTHSF	KQIVNAWQVEQAIYA	GLLLTRDGGGNN---SENETFRPGGGMDRDNW
3468.V1.C12	AD	0.063	ENITNNAKT	FANA-SGGDLEVTTHSF	KQIINMWQRTGQAMYA	GLLLTRDGGDTS----SMNETFRPGGGMDRDNW
0815.V3.C3	ACD	0.042	ENITNNGKN	FNKS-AGGDLEVTTHSF	KQIINMWQRVGQAMYA	GLILTRDGGGNT----NASETFRPGGGMDRDNW
93TH057	AE	0.027	ENLTNNAKT	FQPP-SGGDLEITMHF	KQIINMWQGTGQAMYA	GILLTRDGGANN----TSNETFRPGGGNIKDNW
C3347.c11	AE	0.094	ENLENNAKT	FRPP-LGGDLEITMHF	KQIINMWQGTGQAMYA	GILLTRDGGNNS----ADNETFRPGGGNIKDNW
R2184.c4	AE	0.068	ENLTDNKT	FQPP-SGGDLEITMHF	KQIINMWQRVGQAMYA	GILLTRDGGTNTS---KNNETFRPGGGNIKDNW
R3265.c6	AE	0.054	ENITNNAKT	FRPP-SGGDLEITMHF	KQIINMWQGVGQAMYA	GILLTRDGGDDG---ATNETFRPGGGNIKDNW
DJ263.8	AG	0.108	EDITNNAKN	IFANSSGGDLEITTHSF	KQIVNMWQKVLAMYA	GLLLTRDGGSNNS---TNETFRPGGGMDRDNW
3988.25	B	0.552	ENLTDNAKT	FNQS-SGGDAELVMHSF	KQIINMWQEVGKAMYN	GLLLTRDGGNNNT---NTTETFRPEGGNMKDNW
6101.1	B	0.069	ENLTDNAKT	FNQS-SGGDLEIVMHTF	KQIINRWQEVGKAMYA	GLLLTRDGGDNN---NTTETFRPGGGMDRDNW
BaL.26	B	0.037	ENFTNNAKI	FKHS-SGGDPEIVTHSF	KQIINMWQEVGRAMYA	GLLLTRDGGPE--D--DKTEVFRPGGGMDRDNW
JRFL.JB	B	0.02	DNFTNNAKT	FNHS-SGGDPEIVMHSF	KQIINMWQEVGKAMYA	GLLLTRDGGINEN---GTEIFRPGGGMDRDNW
MN.3	B	0.016	ENFTDNAKT	FNPS-SGGDPEIVMHSF	KQIINMWQKVGKAMYA	GLLLTRDGGEDT-DT-NDTEIFRPGGGMDRDNW
REJO.67	B	0.046	ENFTDNAKI	FNQS-SGGDPEVTMHTF	KQIINMWQRVGKAIYA	GLILTRDGGNSSL---SSPEIFRPGGGMDRDNW
RHPA.7	B	0.045	ENFTNNVKN	FAPS-SGGDPEIVMHSF	RQIINMWQEVGKAMYA	GLLLTRDGGVDT----TKETFRPGGGNMKDNW
TRJO.58	B	0.069	KNFSDNAKI	FNQP-SGGDPEVTMHSF	KQIINRWQEVGKAMYA	GLLLTRDGGKTA--N-NTTEFFRPGGGNMKDNW
CH038.12	BC	0.386	ENLTDNAKI	FESS-SGGDLEITTHSF	KQIINMWQGVGQAMYA	GLLLTRDGGRSNET--NDTETFRPEGGNMKDNW
CH070.1	BC	1.67	ENLTNNAKT	FAPH-SGGDLEITTHSF	RQIVRMWQVVGQAMYA	GLLLVRDGGNI--N--RTNETFRPEGGMDRDNW
CH117.4	BC	0.021	ENLTDNVKT	FTSS-SGGDLEIATHSF	KQIINMWQEVGQAMYA	GLLLERDGGRDIN---NTEIFRPGGGDMKNW
001428-2.42	C	0.026	ENLTDNVKT	FTSS-SGGDLEITTHSF	KQIINMWQEVGRAMYA	GLLLVRDGGKN----NNTETFRPGGGMDRDNW
0077_V1.C16	C	1.03	ENITDNVKT	FQPPSPGGDLEITTHSF	KQIINMWQGVGRAMYA	GILLTRDGGSETNDGNTTETEIFRPGGGMDRDNW
00836-2.5	C	0.242	KKLDDNANT	FNSS-SGGDLEITTHSF	KQVINLWQEVGQAIYA	GLLLVRDGGNHEEA--NTTETFRPGGGMDRDNW
16936-2.21	C	0.046	ENLTDNVKT	FNSS-SGGDLEITTHSF	KQIVNMWQKVGKAMYA	GLLLVRDGGPD----NVTEIFRPGGGMDRDNW
25711-2.4	C	0.793	ENITDNAKT	FNSS-SGGDLEITTHSF	KQIINMWQEVGRAMYA	GILLTRDGGRGEEVK--NDTETFRPGGGNMKDNW
3637.V5.C3	C	4.6	ENITDNVKT	KQPS-PGGDLEITMHSF	KQIINMWQEVGRAMYA	GLLLVRDGGISNGTD--NKNETFRPGGGMDRNW
DU151.02	C	2.51	ENLTNNIKT	FKPP-SGGDLEVTTHSF	KQIINMWQKVGKAMYA	GLLLTRDGGK--N---TTNETIFRPGGGNMKDNW
DU156.12	C	0.088	ENLTDNIKT	FEPP-SGGDLEITTHSF	KQIINMWQGVGRAMYA	GLLLTRDGGGNVTEI--NRTEIFRPGGGNMKDNW
TZBD.02	C	0.07	KNLTNNVNT	FKPS-SGGDLEITTHSF	KQIVNMWQEVGRAMYA	GLLLVRDGGGES---NETEIFRPGGGMDRDNW
ZM176.66	C	0.055	ENLTDNAKT	FEPP-SGGDLEITTHSF	KQIVNMWQGVGRAMYA	GLLLTRDGGNDD---NDTETFRPGGGMDRDNW
3326.V4.C3	CD	0.087	ENLTNNVKN	FEPA-LGGDPEITHTF	KQIINMWQGVGKAMYA	GLLLTRDGGNSH-----ETFRPGGGMDGNW
3337.v2.c6	CD	0.026	ENITNNAKT	FQPS-SGGDPEITEHTF	KQIINRWQGVGKAMYA	GLLLTRDGGNT-----SEEIFRPGGGMDRDNW
3016.v5.c45	D	0.193	ENISNNAYN	FKPS-AGGDLEITTHSF	KQIINMWQGVGKAMYA	GLILTRDGGNT--S--DHETFRPGGGNMKDNW
A03349M1.vrc4a	D	2.94	ENLTNNAKI	FKPS-SGGDPEITTHSF	KQIINMWQGVGKAMYA	GLLLTRDGGGNE--S--SQNETFRPGGGMDRDNW
UG024.2	D	0.157	ENITNNAKI	FKPS-SGGDPEITTHSF	KQIVNMWQGVGKAMYA	GLLLTRDGGN--T---SQNETFRPGGGMDRDNW
6540.v4.c1	AC	>50	EHIGNSAKN	FKNS-SGGDLEITTHSF	KQIINMWQRAGQAIYA	GLILTSYDYGNN--N---SDNEIFRPTGGGMDRDNW
6545.V4.C1	AC	>50	EDITNSVKN	FKNS-SGGDLEITTHSF	KQIINMWQRAGQAIYA	GLILTSYDYGNR--S---SDNETFRPTGGGMDRDNW
620345.c1	AE	>50	EDITKNKT	FQPP-SGGDLEVTTHSF	KQIVRMWQGVGQSMYA	GILLTSYDGGGP-T--ADNETFRPAGGMDRDNW
242-14	AG	>50	ENISNNGKT	FTNH-SGGDLEVTTHSF	KQIINMWQRVGQAMYA	GLLLTRDGGFRNDTN--ETYEAFRPGGGMDRDNW
T278-50	AG	>50	KNISANAKT	FTKP-SGGDLEITTHSF	KQIINMWQTVGQAMYA	GLLLTRDGEAG--K--STNETFRPIGNNMRDNW
BL01.DG	B	>50	KNFTQNAET	FNPIRGDPEIVMHSF	KQIINLWQKVGKAMYA	GLLLTRDGGKNGT---EGTEIFRPIGNNMRDNW
H086.8	B	>50	ENFTKNEKT	FNQS-TGGDPEITMHTF	RQIVNMWQRIKQAMYA	GLLLTRDGGDN--N---KSTEVFRPIGGMMDRDNW
7165.18	B	>50	ENFTDNVKT	FMQH-SGGDPEIVTHF	KQIINMWQGVGKAMYA	GLLLTRDGGENRTD--NGTEIFRPGGGNMMDRDNW
CAP210.E8	C	>50	ENISNNVKT	FAPP-VGGDLEITTHSF	RQIINMWQEVGRAMYA	GLLLTRDGGENKTEN--NDTEIFRPGGGMDKDNW
DU172.17	C	>50	ENLTNNAKI	FAPS-SGGDLEITTHSF	KQIIRMWQGVGQAMYA	GLLLTRDGGKE--K--NDTETFRPGGGMDRDNW
DU422.01	C	>50	ENLTNNIKT	FEPS-SGGDLEVTTHSF	KQIINMWQEVGRAMYA	GLLLTWDGGEN----STEGVFRPGGGNMKDNW
TV1.29	C	>50	ENLTENTKT	QFKPHAGGDLEITMHSF	KQIVRMWQGVGQAMYA	GILLTRDGGFNTT---NNTETFRPGGGMDRDNW
TZA125.17	C	>50	ENLTNNAKT	FKPAVVGDDLEITTHSF	KQFVNMWQRVGRAMYA	GLLLTWDGGNNT---NGTETFRPGGGMDRDNW
6322.V4.C1	C	>50	ENLTNNAKI	FQPH-SGGDLEVTTHSF	KQIINMWQEVGRAMYA	GLLLERDGGKDN--N--MTEIFRPGGGMDRDNW
6471.V1.C16	C	>50	KDLNNTGNT	FSPH-PGGDLEVTMHSF	KQIINMWQGVARAMYA	GLLLTWDGDKTSND--PDTDVFRPGGGNMKDNW
6631.V3.C10	C	>50	ENLTNNAKI	FESH-SGGDLEITTHSF	KQIINMWQEVGRAMYA	GILLTRDGGPN----STNETFRPEGGMDRNW
3817.v2.c59	CD	>50	ENVTNNAKT	FSPS-SGGDPEITTHSF	KQIVNMWQGVGRAMYA	GLLLTRDGGGLNT---SNNETFRPGGGMDRDNW
57128.vrc15	D	>50	ENLTNNAKI	FNAS-SGGDPEITTHSF	KQIINMWQGVGKAMYA	GLLLTRDGGGDANN--RQNETFRPGGGMDRDNW
X2088.c9	G	>50	ENLTNNAKV	FNSP-AGGDLEITTHSF	KQIVRMWQRVGQAMYA	GLLLTRDGVNDTHD---KENETFRPTGGGMDRDNW

Table S1: Overview of the selected gp120 HIV-1 strains from a diversity of clades.

Strain name	Clade	VRC01	NIH45-46	3BNC117
3988.25	B	Sensitive	Sensitive	Resistant
7165.18	B	Resistant	Resistant	Sensitive
MN.3	B	Sensitive	Sensitive	Resistant
CH038.12	BC	Sensitive	Sensitive	Resistant
CAP210.E8	C	Resistant	Resistant	Sensitive
DU172.17	C	Resistant	Resistant	Sensitive
UG024.2	D	Sensitive	Resistant	Sensitive
3016.v5.c45	D	Sensitive	Resistant	Sensitive
57128.vrc15	D	Resistant	Resistant	Sensitive

Table S2: Sensitive and resistant strains towards three anti-CD4bs antibodies.




Figure S1. Experimental IC50 determinations (µg/mL) of the VRC01 sensitive strains evaluated in this work. As can be observed, most of all binding determinations have values < 0.2 µg/mL.




Figure S2. Experimental IC50 determinations (µg/mL) of the VRC01 sensitive strains evaluated in this work. A numerical value 50µg/mL was assumed, since the current experimental data is “>50µg/mL” for all of those strains.